Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,607 signal articles · 119 in last 24h · 155,469 total before filter · latest 26m ago
119last 24h
855last 7d
146● bullish (7d)
90● bearish (7d)
214publishers
AllMacro191Earnings105M&A126Regulatory20Product22Analyst19
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Is Biogen (BIIB) Undervalued On Raised EPS Guidance And Key Phase 3 Readouts?
Simply Wall St.35d agoneutral
Is Biogen (BIIB) Undervalued On Raised EPS Guidance And Key Phase 3 Readouts?

Biogen (BIIB) is back in focus after management raised non GAAP EPS guidance, citing expected launch growth and five upcoming Phase 3 readouts in lupus, transplant and rare diseases. See our latest analysis for Biogen. Biogen's recent guidance upgrade comes after a period of renewed momentum, with the share price at US$214.35 and a 30 day share price return of about 8%, while the 1 year total shareholder return of around 54% contrasts with weaker 3 and 5 year total shareholder returns. This...